TELA Bio, Inc. (TELA) - Q1 2025 10-Q Summary
Business Context and Reporting Period
TELA Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, primarily through its OviTex (hernia repair) and OviTex PRS (plastic and reconstructive surgery) product portfolios. The company operates as a single reportable segment. This report covers the quarterly period ended March 31, 2025.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $18.5 million | $16.6 million |
| Gross Profit | $12.5 million | $11.3 million |
| Gross Margin | 68% | 68% |
| Net Loss | $(11.3) million | $(5.7) million |
| Net Loss Per Share (Basic/Diluted) | $(0.25) | $(0.23) |
| Cash and Cash Equivalents | $42.8 million | $37.1 million |
| Working Capital | $53.2 million | $62.5 million (Dec 2024) |
| Long-Term Debt | $41.3 million | $41.1 million |
| Accumulated Deficit | $(370.0) million | $(326.6) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 12% year-over-year, driven by a 29% increase in unit sales of OviTex hernia products and new customer additions. This was partially offset by a decrease in average selling prices due to a shift toward smaller-sized units.
- Net Loss Expansion: Net loss nearly doubled (99% increase) to $11.3 million. This increase is primarily attributable to the absence of a $7.6 million one-time gain recognized in Q1 2024 from the sale of the NIVIS product line to MiMedx Group, Inc.
- Operating Expenses: Total operating expenses decreased 3% to $23.0 million. Sales and marketing expenses declined 5% due to lower headcount and travel costs, while R&D expenses increased 6% due to higher study costs.
- Cash Flow: Net cash used in operating activities improved to $9.7 million from $14.4 million in the prior year, reflecting the non-cash nature of the prior year's asset sale gain.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes existing cash resources ($42.8 million) are sufficient to fund operations for at least the next 12 months. The company maintains an at-the-market (ATM) equity offering program with Piper Sandler, though no sales were made in Q1 2025.
- Debt Covenants: The company holds a $40.0 million term loan with MidCap Financial Trust maturing in May 2027. It must maintain minimum net revenue levels tested quarterly. Default would trigger a 2% interest rate penalty.
- Macroeconomic Risks:
- Tariffs: A 10% U.S. tariff on imports from New Zealand (where products are manufactured) is currently in effect. Costs are shared equally with the manufacturer, but price increases may be necessary, potentially impacting demand.
- Cybersecurity: Ransomware attacks on hospital systems in Q2 2024 reduced procedural volumes, a risk that persists.
- Supply Chain: Disruptions in critical surgical supplies (e.g., IV fluids) could lead to elective procedure deferrals.
- Product Updates: In March 2025, the company launched larger sizes of OviTex PRS. The company continues to pursue FDA approval for OviTex PRS in implant-based breast reconstruction.
Investor Verification Checklist
- Debt Covenant Compliance: Verify that the company continues to meet the minimum net revenue covenants required by the MidCap Credit Agreement to avoid default penalties.
- Tariff Impact: Monitor the company's ability to pass on tariff-related costs to customers without significantly eroding sales volume or market share.
- Cash Burn Rate: Assess the sustainability of the current cash burn rate (~$10M/quarter operating cash use) against the $42.8M cash balance to confirm the 12-month runway.
- Revenue Quality: Analyze the trend in average selling prices (ASP) to ensure the shift to smaller unit sizes does not permanently depress revenue growth.
- Regulatory Progress: Track the status of the FDA investigational device exemption (IDE) study for OviTex PRS in breast reconstruction, a key growth driver.